About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/17/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/17/2021.

Atrial Sensing Capability for Better Detection of Atrial Fibrillation

Clinicaltrials.gov identifier NCT03932604

Recruitment Status Not yet recruiting

First Posted May 1, 2019

Last update posted May 2, 2019

Study Description

Brief summary:

This prospective multi center randomized controlled study aims to determine whether the comparison of atrial fibrillation detection according to activation of atrial sensing capability in patients with implantable cardioverter defibrillator.

  • Condition or Disease:Implantable Cardioverter Defibrillator
    Atrial Fibrillation
    Cardiac Event
    Cardiac Arrhythmia
  • Intervention/Treatment: Device: Atrial sensing On mode
  • Phase: N/A
Detailed Description

Implantable cardioverter defibrillators(ICD) therapy has been shown to reduce sudden cardiac death and improve survival in cardiac arrest survivors as well as in heart failure patients with left ventricular dysfunction. Atrial fibrillation (AF) is commonly found in ICD implantation patients up to 50%. AF is an independent predictor of mortality, inappropriate shock, and embolic events. Therefore, early detection of AF in patients with ICD is essential for improving the quality of life and overall prognosis of the patients. Conventional ICDs consist of a single chamber (SC) ICD with a lead only in the right ventricle (RV) and dual chamber (DC) ICD with each lead in the right atrium (RA) and RV. SC ICD has the advantage of shorter procedure time, lower cost compared to DC ICD. In contrast, DC ICD has the advantage of being able to monitor atrial arrhythmic events, but complication rates were higher and additional cost and longer procedure time are usually required than SC ICD. Sixty percent of ICD implantation patients who have are SC ICD Recently, a unique ICD lead with atrial sensing ring capable of monitoring the atrial electrical signals has been developed [Intica 7 VR-T DX ICD (Biotronik., Germany)]. Therefore, turning off the atrial sensing function makes it functionally the same as SC ICD whereas turning on makes it function similar to DC ICD without additional cost and procedure time. Therefore, Detection of AF could be made earlier with VDD ICD versus conventional SC ICD without atrial sensing capability, providing a better chance to improve the prognosis of ICD patients. However, no study exists which shows whether VDD ICD is better for detecting atrial tachyarrhythmia than conventional SC ICD. Therefore, we designed a multicenter prospective randomized study comparing the AF diagnostic efficacy of VDD ICD (with atrial sensing 'ON') against conventional SC ICD. .

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 280 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: Patients are randomly assigned as atrial sensing ON or Off mode
  • Masking: None (Open Label) ()
  • Primary Purpose: Screening
  • Official Title: A Prospective, Multicenter, Randomized Controlled Trial Comparing Atrial Sensing ON-mode of VDD Implantable Cardioverter Defibrillator(ICD) to Atrial Sensing OFF-mode of VDD ICD in Detecting Atrial Fibrillation(Smart-Control Study)
  • Estimated Study Start Date: June 2019
  • Estimated Primary Completion Date: May 2021
  • Estimated Study Completion Date: May 2023
Arms and interventions
Arm Intervention/treatment
Active Comparator: Atrial sensing ON mode
VDD-ICD programmed as atrial sensing ON mode
Device: Atrial sensing On mode
Single lead VDD-ICD programmed as atrial sensing On mode.
Outcome Measures
  • Primary Outcome Measures: 1. Atrial fibrillation [ Time Frame: from enrollment to last follow-up (2 years) ]
    cardiac implantable electronic device-detected or clinical atrial fibrillation
  • Secondary Outcome Measures: 1. Number of Participants with inappropriate shock [ Time Frame: from enrollment to last follow-up (2 years) ]
    Any ICD therapy not delivered for ventricular tachycardia or ventricular fibrillation
  • 2. Number of Participants with complications associated with atrial fibrillation [ Time Frame: from enrollment to last follow-up (2 years) ]
    thromboembolic events, heart failure
  • 3. Number of Participants with ventricular arrhythmia [ Time Frame: from enrollment to last follow-up (2 years) ]
    cardiac implantable electronic device-detected or clinical ventricular arrhythmia
  • 4. Number of Participants with major adverse composite events [ Time Frame: from enrollment to last follow-up (2 years) ]
    cardiac death, all cuase death, stroke, atrial fibrillation or flutter, ventricular tachyarrhythmia, hospitalization for heart failure
  • 5. atrial lead sensing stability [ Time Frame: from enrollment to last follow-up (2 years) ]
    Atrioventricular synchrony ratio
Eligibility Criteria
  • Ages Eligible for Study: 19 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

1. age ≥ 19 years

2. indication for ICD implantation according to guidelines

3. atrial fibrillation didn't detect by electrocardiogram or Holter test within the past
1 year from the ICD implantation, and

4. CHA2DS2VASc score ≥1 point in male or ≥ 2 in female

Exclusion Criteria:

1. persistent or permanent atrial fibrillation (AF)

2. atrial fibrillation detected by electrocardiogram or Holter test within the past 1
year from the ICD implantation

3. history of the catheter or surgical ablation of AF or taking antiarrhythmic drug

4. scheduled to undergo heart transplant within 1 year

5. life expectancy < 1 year 6. requiring atrial pacing

Contacts and Locations
Contacts

Contact: Seung-Jung Park, PhD +82-2-3410-7145 orthovics@gmail.com

Locations
Show 28 Study Locations
Sponsors and Collaborators

Samsung Medical Center

Biotronik SE & Co. KG

Investigators

Principal Investigator: Seung-Jung Park, PhD Samsung Medical Center

More Information
  • Responsible Party: Samsung Medical Center
  • ClinicalTrials.gov Identifier: NCT03932604 History of Changes
  • Other Study ID Numbers: SMC-2019-01-149-03
  • First Posted: May 1, 2019 Key Record Dates
  • Last Update Posted: May 2, 2019
  • Last Verified: April 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Atrial Fibrillation Arrhythmias, Cardiac